REG - Wellnex Life Limited - Extension of Haleon Licensing and Supply Agreement

Wellnex LifeAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260402:nRSB1603Za&default-theme=true

RNS Number : 1603Z  Wellnex Life Limited  02 April 2026

 

ASX/AIM Announcement

 
 
 
2 April 2026

Extension of Haleon Licensing and Supply Agreement

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is
pleased to announce that the Company, through its wholly owned subsidiary BSPS
Aust Pty Ltd, has signed an extension to the existing licensing and supply
agreement (the "Agreement") originally entered into on 16 March 2022 between
the Company, Haleon UK Trading Services Ltd ("Haleon UK") and Olive
Pharmascience Ltd. The Agreement, for the supply to Haleon UK of soft gel
liquid paracetamol products, has been extended until 16 March 2027.

Eric Jiang Interim Executive Chairman said, "The Company is proud to continue
its global partnership with Haleon, supporting their global brands with our
innovative analgesic liquid soft gels."

This ASX/AIM announcement has been authorised by the Board of Wellnex Life
Limited (ASX/AIM:WNX).

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)
 

Eric Jiang
 

Interim Executive
Chairman

E: eric.j@wellnexlife.com.au (mailto:eric.j@wellnexlife.com.au)

 

UK Investors

Strand Hanson (Financial & Nominated Advisor)

 

James Harris / Richard Johnson
                     Tel: +44 (0) 20 7409 3494

 

Orana Corporate LLP (Joint
Broker)
swykeham@oranacorp.com (mailto:swykeham@oranacorp.com)

Sebastian Wykeham

 

S.P. Angel Corporate Finance LLP (Joint Broker)
      Tel: +44 (0)20 3470 0470

David Hignell / Vadim Alexandre

 

To learn more, please visit: https://wellnexlife.com.au/
(https://wellnexlife.com.au/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRIBMTTMTAMTMF



            Copyright 2019 Regulatory News Service, all rights reserved